Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | 0 | uM | 9 | 2500.00 | 1861.36 | 4313.00 | 4181.50 | 1.0314 | 1.0537 | |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 2500.00 | 1861.36 | 1719.00 | 4181.50 | 0.4111 | -0.0659 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 2500.00 | 1861.36 | 2566.00 | 4181.50 | 0.6137 | 0.3165 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 2500.00 | 1861.36 | 3942.00 | 4181.50 | 0.9427 | 0.9015 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 2500.00 | 1861.36 | 1920.00 | 4181.50 | 0.4592 | 0.0269 |
| SK-BR-3 | 0 | uM | 9 | 2500.00 | 1861.36 | 3876.00 | 4181.50 | 0.9269 | 0.8742 | |
| SK-BR-3 | 0 | uM | 9 | 5000.00 | 3570.27 | 6612.00 | 6353.50 | 1.0407 | 1.0983 | |
| SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 5000.00 | 3570.27 | 6275.00 | 6353.50 | 0.9876 | 0.9703 |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 5000.00 | 3570.27 | 6290.00 | 6353.50 | 0.9900 | 0.9760 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 5000.00 | 3570.27 | 6355.00 | 6353.50 | 1.0002 | 1.0006 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 5000.00 | 3570.27 | 6397.00 | 6353.50 | 1.0068 | 1.0165 |
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 5000.00 | 3570.27 | 3015.00 | 6353.50 | 0.4745 | -0.1840 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 5000.00 | 3570.27 | 6416.00 | 6353.50 | 1.0098 | 1.0237 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 5000.00 | 3570.27 | 6485.00 | 6353.50 | 1.0207 | 1.0499 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 5000.00 | 3570.27 | 6523.00 | 6353.50 | 1.0267 | 1.0643 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 5000.00 | 3570.27 | 2964.00 | 6353.50 | 0.4665 | -0.2005 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 5000.00 | 3570.27 | 5040.00 | 6353.50 | 0.7933 | 0.5138 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 5000.00 | 3570.27 | 5820.00 | 6353.50 | 0.9160 | 0.7998 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 5000.00 | 3570.27 | 3472.00 | 6353.50 | 0.5465 | -0.0330 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 5000.00 | 3570.27 | 6353.00 | 6353.50 | 0.9999 | 0.9998 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 5000.00 | 3570.27 | 6343.00 | 6353.50 | 0.9984 | 0.9960 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 5000.00 | 3570.27 | 5709.00 | 6353.50 | 0.8986 | 0.7586 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 5000.00 | 3570.27 | 2723.00 | 6353.50 | 0.4286 | -0.2781 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 5000.00 | 3570.27 | 6481.00 | 6353.50 | 1.0201 | 1.0484 |
| SK-BR-3 | 0 | uM | 9 | 5000.00 | 3570.27 | 6312.00 | 6353.50 | 0.9935 | 0.9843 |